{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:30:54Z","timestamp":1769023854430,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32 CA101642"],"award-info":[{"award-number":["T32 CA101642"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck MDS"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100020984","name":"Cedars Cancer Foundation","doi-asserted-by":"crossref","award":["Dr. Henry R. Shibata Fellowship Award"],"award-info":[{"award-number":["Dr. Henry R. Shibata Fellowship Award"]}],"id":[{"id":"10.13039\/501100020984","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ovarian SPORE","award":["P50CA217685"],"award-info":[{"award-number":["P50CA217685"]}]},{"DOI":"10.13039\/100013028","name":"Frank McGraw Memorial Chair in Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1P50CA217685-01"],"award-info":[{"award-number":["1P50CA217685-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gynecologic Oncology Group Foundation","award":["Scholar Investigator Award"],"award-info":[{"award-number":["Scholar Investigator Award"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10637-020-01043-9","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T21:03:26Z","timestamp":1610053406000},"page":"829-835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1446-9574","authenticated-orcid":false,"given":"Jeffrey A.","family":"How","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois M.","family":"Ramondetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Abonofal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi A.","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"6","key":"1043_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1200\/JCO.2003.10.019","volume":"21","author":"ST Schumer","year":"2003","unstructured":"Schumer ST, Cannistra SA (2003) Granulosa cell tumor of the ovary. J Clin Oncol 21(6):1180\u20131189","journal-title":"J Clin Oncol"},{"issue":"1","key":"1043_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1006\/gyno.1994.1010","volume":"52","author":"H Malmstr\u00f6m","year":"1994","unstructured":"Malmstr\u00f6m H et al (1994) Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 52(1):50\u201355","journal-title":"Gynecol Oncol"},{"key":"1043_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejogrb.2018.04.002","volume":"225","author":"G Levin","year":"2018","unstructured":"Levin G et al (2018) Granulosa cell tumor of ovary: A systematic review of recent evidence. Eur J Obstet Gynecol Reprod Biol 225:57\u201361","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10 Suppl","key":"1043_CR4","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/cncr.11345","volume":"97","author":"VW Chen","year":"2003","unstructured":"Chen VW et al (2003) Pathology and classification of ovarian tumors. Cancer 97(10 Suppl):2631\u20132642","journal-title":"Cancer"},{"issue":"8","key":"1043_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/00000478-198408000-00002","volume":"8","author":"RH Young","year":"1984","unstructured":"Young RH, Dickersin GR, Scully RE (1984) Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol 8(8):575\u2013596","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1043_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/bjc.2013.241","volume":"109","author":"G Mangili","year":"2013","unstructured":"Mangili G et al (2013) Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. Br J Cancer 109(1):29\u201334","journal-title":"Br J Cancer"},{"key":"1043_CR7","doi-asserted-by":"crossref","unstructured":"Gurumurthy M, Bryant A, Shanbhag S (2014) Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent). Cochrane Database Syst Rev 2014(4):Cd006912","DOI":"10.1002\/14651858.CD006912.pub2"},{"issue":"26","key":"1043_CR8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454","journal-title":"N Engl J Med"},{"issue":"8","key":"1043_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"key":"1043_CR10","unstructured":"Le DT et al. (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (New York, N.Y.)\u00a0357(6349):409\u2013413"},{"issue":"1","key":"1043_CR11","first-page":"e00034","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A et al (2020) Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1):e00034","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1043_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ygyno.2020.05.682","volume":"158","author":"M Frumovitz","year":"2020","unstructured":"Frumovitz M et al (2020) Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol 158(3):570\u2013575","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1043_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s10637-017-0534-0","volume":"36","author":"T Fujii","year":"2018","unstructured":"Fujii T et al (2018) Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36(4):638\u2013646","journal-title":"Invest New Drugs"},{"issue":"1","key":"1043_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152(1):45\u201351","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1043_CR15","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1016\/j.cllc.2020.01.003","volume":"21","author":"K Hosoya","year":"2020","unstructured":"Hosoya K et al (2020) Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Clin Lung Cancer 21(4):e315\u2013e328","journal-title":"Clin Lung Cancer"},{"issue":"19","key":"1043_CR16","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20(19):5064\u20135074","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1043_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"key":"1043_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2018.07.010","volume":"130","author":"T Fujii","year":"2018","unstructured":"Fujii T et al (2018) Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol 130:108\u2013120","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"1043_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/ijgc-2018-000065","volume":"29","author":"AM Mills","year":"2019","unstructured":"Mills AM et al (2019) Emerging biomarkers in ovarian granulosa cell tumors. Int J Gynecol Cancer 29(3):560\u2013565","journal-title":"Int J Gynecol Cancer"},{"key":"1043_CR20","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/jco.19.02059","volume":"38","author":"D Zamarin","year":"2020","unstructured":"Zamarin D et al (2020) Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol 38:1814\u20131823. https:\/\/doi.org\/10.1200\/jco.19.02059","journal-title":"J Clin Oncol"},{"issue":"9","key":"1043_CR21","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran MA et al (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107(9):4275\u20134280","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1043_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/jmg.39.12.916","volume":"39","author":"J Cocquet","year":"2002","unstructured":"Cocquet J et al (2002) Evolution and expression of FOXL2. J Med Genet 39(12):916\u2013921","journal-title":"J Med Genet"},{"issue":"26","key":"1043_CR23","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","volume":"360","author":"SP Shah","year":"2009","unstructured":"Shah SP et al (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 360(26):2719\u20132729","journal-title":"N Engl J Med"},{"issue":"6","key":"1043_CR24","doi-asserted-by":"publisher","first-page":"e0178989","DOI":"10.1371\/journal.pone.0178989","volume":"12","author":"S Yanagida","year":"2017","unstructured":"Yanagida S et al (2017) Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C > G FOXL2 mutation. PLoS One 12(6):e0178989","journal-title":"PLoS One"},{"issue":"1","key":"1043_CR25","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1038\/s41467-018-04950-x","volume":"9","author":"RT Hillman","year":"2018","unstructured":"Hillman RT et al (2018) KMT2D\/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. Nat Commun 9(1):2496","journal-title":"Nat Commun"},{"key":"1043_CR26","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41379-020-0514-3","volume":"33","author":"Da C Paula","year":"2020","unstructured":"Paula Da C, A, et al (2020) Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary. Mod Pathol 33:1606\u20131617","journal-title":"Mod Pathol"},{"issue":"5","key":"1043_CR27","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/cancers12051308","volume":"12","author":"J Roze","year":"2020","unstructured":"Roze J et al (2020) Whole genome analysis of ovarian granulosa cell tumors reveals tumor heterogeneity and a high-grade TP53-specific subgroup. Cancers (Basel) 12(5):1308","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1043_CR28","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16(11):2598\u20132608","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1043_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ygyno.2009.04.021","volume":"114","author":"X Tao","year":"2009","unstructured":"Tao X et al (2009) Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114(3):431\u2013436","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1043_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/EJE-10-0849","volume":"164","author":"A F\u00e4rkkil\u00e4","year":"2011","unstructured":"F\u00e4rkkil\u00e4 A et al (2011) Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. Eur J Endocrinol 164(1):115\u2013122","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1043_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/cncr.28421","volume":"120","author":"J Brown","year":"2014","unstructured":"Brown J et al (2014) Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 120(3):344\u2013351","journal-title":"Cancer"},{"key":"1043_CR32","doi-asserted-by":"publisher","unstructured":"Ray-Coquard I et al (2020) Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: the ALIENOR\/ENGOT-ov7 randomized clinical trial. JAMA Oncol:e204574. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4574","DOI":"10.1001\/jamaoncol.2020.4574"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01043-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-01043-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01043-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:03:48Z","timestamp":1678511028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-01043-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1043"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-01043-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"23 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The views expressed in this manuscript are the authors\u2019 own views and are not the official position of the institution or supporting funding sources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The protocol was approved by the US Food and Drug Administration (FDA) and the Institutional Review Board at The University of Texas MD Anderson Cancer Center. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All of the study participants provided written informed consent before enrollment.\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All of the study participants provided written informed consent prior to clinical trial enrollment.\u00a0","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation and publication"}},{"value":"Jeffrey How reports grants from the NIH (T32 CA101642) and the Cedars Cancer Foundation during the conduct of the study.Amir Jazaeri reports personal fees from Gerson and Lehrman Group, Guidepoint, Iovance Advisory Board Meeting, Nuprobe, Simcere, and Pact Pharma; grants from AstraZeneca, BMS, Iovance, Aravive, Pfizer, Immatics USA, and Eli Lilly; and other funding from AstraZeneca outside of the submitted work.Shannon N. Westin reports grants from the NIH and the GOG Foundation during the conduct of the study; grants and personal fees from AstraZeneca, Clovis Oncology, GSK\/Tesaro, Roche\/Genentech, and Novartis; personal fees from Merck, Pfizer, Eisai, CIrculogene, and Zentalis; and grants from Cotinga Pharmaceuticals, Bayer, and ArQule outside of the submitted work.Anil K. Sood reports grants from the NIH (CA109298 and CA209904) during the conduct of the study and other funding from Merck, Biopath, Kiyatec, and M-Trap outside of the submitted work.Vivek Subbiah reports grants and other funding from LOXO Oncology\/Eli Lilly, Novartis, Pharmamar, and Medimmune; grants from Roche\/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, the National Comprehensive Cancer Network, NCI-CTEP, The University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, and Boston Pharmaceuticals; and other funding from Helsinn, R-Pharma US, Incyte, QED Pharma, ASCO, ESMO, and Medscape during the conduct of the study.Jordi A. Rodon reports personal fees from Eli Lilly, Orion Pharmaceuticals, Peptomyc, Roche Pharmaceuticals, Ellipses Pharma, Certera, and Ionctura SA; personal fees and other funding from Kelun Pharmaceuticals\/Klus Pharma, Novartis, Spectrum Pharmaceuticals, Inc., Pfizer, and Bayer; and other funding from <i>European Journal of Cancer<\/i>, VHIO\/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, SOLTI, Elsevier, GlaxoSmithKline, ESMO, Department of Defense, Merck Sharp & Dohme, Louisiana State University, Huntsman Cancer Institute, Cancer Core Europe, Karolinska Cancer Institute, King Abdullah International Medical Research Center, WIN Consortium, Janssen, Tocagen, Symphogen, BioAlta, GenMab, CytomX, Kelun-Biotech, Takea-Millenium, and Ipsen outside of the submitted work.Aung Naing reports grants from NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Eli Lilly, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, BMS, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Kymab, PsiOxus, and Immune Deficiency Foundation (spouse) and other funding from CytomX Therapeutics, Novartis, Kymab, Genome, and ARMO BioSciences outside of the submitted work.Lois M. Ramondetta, Mingxuan Xu, Abdulrahman Abonofal, Daniel D. Karp, Bettzy Stephen, and Fei Yang have no conflicts of interest to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}